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Summary
Objective: To simultaneously study the effect of a selective cyclooxygenase-2 (COX-2) inhibitor and that of a classic non-steroidal anti-inﬂam-
matory drug (NSAID) on the expression of pro-inﬂammatory genes in the cartilage of patients with severe knee osteoarthritis (OA) and in cul-
tured human OA chondrocytes.
Methods: A 3-month clinical trial was carried out on 30 patients with severe kneeOA scheduled for knee replacement surgery. Patients were ran-
domized into two groups: patients treated with celecoxib (CBX) and patients treated with aceclofenac (ACF). OA patients who did not want to be
treated served as the control group. After surgery, cartilage was processed for molecular biology studies. We also employed cultured chondro-
cytes from different OA patients to examine NSAID effects on pro-inﬂammatory gene expression in cells stimulated with interleukin (IL)-1b.
Results: Both CBX and ACF inhibited COX-2, microsomal prostaglandin E synthase-1 (mPGES-1) and inducible nitric oxide synthase (iNOS)
synthesis in the articular cartilage of OA patients. In cultured chondrocytes, both NSAID decreased COX-2 and mPGES-1 synthesis and
prostaglandin E2 (PGE2) release induced by IL-1b, while no effect was observed on nitric oxide or iNOS synthesis. In OA patients, only
CBX decreased tumor necrosis factor alpha and IL-1b expression in the cartilage, while both NSAID diminished IL-1b induced cytokine
synthesis in cultured OA chondrocytes.
Conclusions: Both NSAID diminished PGE2 release and induced a decrease in COX-2 and mPGES-1 synthesis in the cartilage from OA
patients and in OA chondrocytes. These data suggest that prolonged therapy with PGE2 blocking agents decreases PGE2 production not
only by direct inhibition of COX-2 activity, but also by down-regulating COX-2 and mPGES-1 synthesis in the cartilage. However, CBX
and ACF seem to have a different anti-inﬂammatory proﬁle in controlling pro-inﬂammatory gene expression in the cartilage.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is characterized by the degeneration of
cartilage matrix components together with an excessive
production of different cytokines. Interleukin (IL)-1b in-
creases the synthesis of many pro-inﬂammatory mediators
such as the inducible nitric oxide synthase (iNOS), cycloox-
ygenase-2 (COX-2), microsomal prostaglandin E synthase-
1 (mPGEs-1), and matrix metalloproteinases, and, hence, it
promotes the release of nitric oxide (NO) and prostaglandin
E2 (PGE2)1e4. Similarly, IL-1b also retards anabolic activi-
ties in chondrocytes that leads to a decline in proteoglycan
and collagen synthesis5,6.
NO is also implicated in joint inﬂammation and the structural
deterioration observed during OA7e9. NO inhibits matrix syn-
thesis and induces its degradation, and promote cell injury7e9.*Address correspondence and reprint requests to: Dr R. Largo,
Ph.D., Joint and Bone Research Unit, Fundacio´n Jime´nez Dı´az,
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1484iNOS is the key enzyme responsible for NO generation in in-
ﬂammatory and pathological processes, including OA. NO
synthesis seems to take place mostly in the cartilage during
OA10, and its accumulation correlates with the joint
destruction11.
PGE2 is the eicosanoid found at the highest concentra-
tions in OA joints, and it can be synthesized by chondro-
cytes, synoviocytes and macrophages12. PGE2 regulates
many processes, including the release of inﬂammatory
mediators, cell apoptosis, neoangiogenesis, the synthesis
of structural mediators, and even symptoms of OA12e14.
In fact, for decades, elements that control PGE2 synthesis
have been the main targets in OA therapy. In the cartilage,
PGE2 can exert anabolic and pro- or anti-catabolic
effects13. PGE2 inhibited proteoglycan degradation15 and
prevented the release of metalloproteases16. At the same
time, PGE2 inhibition prevented cytokine-induced cartilage
damage17 and increased proteoglycan synthesis in OA
cartilage18,19. The different effects induced by PGE2 in
the cartilage may largely depend on its binding to different
cell surface prostaglandin E receptors (EP receptors),
each coupled to a distinct cell response20. However,
1485Osteoarthritis and Cartilage Vol. 16, No. 12despite the clear importance there is still little known about
the regulation of EP receptors during OA.
Non-steroidal anti-inﬂammatory drug (NSAID) are com-
monly used to treat symptoms of OA and, in many cases,
they are employed over extended periods21. The therapeu-
tic efﬁcacy of NSAID in modulating pain and inﬂammation
has been attributed to its ability to impair PGE2 release
by inhibiting COX enzyme activity, although their direct ef-
fects on cartilage are still to be fully deﬁned. There is grow-
ing interest in the effects of NSAID and of speciﬁc COX-2
inhibitors on cartilage, although these effects cannot be
easily studied in clinical trials since the changes in cartilage
during OA are rather slow process. To date, most of the in-
formation on how NSAID act comes from short-term cell or
explants cultures studies and although many patients with
OA have taken these drugs for several years, few studies
have evaluated the long-term effects of NSAID.
Therefore, the aim of this study was to examine the effect
of a speciﬁc COX-2 inhibitor, as well as that of a classic
NSAID, on the expression of pro-inﬂammatory genes in
the articular cartilage of patients with severe knee OA and
in human OA chondrocytes in culture.
Patients and methodsPATIENTSIn this study, we evaluated the effect of the NSAID in the articular cartilage
of the same OA patients included in a previous work in which we analyzed
synovial inﬂammation associated to OA22. In the study were included 30
patients with clinical and radiological evidences of knee OA that had been
scheduled for total knee replacement surgery (Hospital Virgen de la Cinta,
Tortosa, Tarragona, Spain). The patients included in the study that agreed
to NSAID therapy were randomized into two groups that received either
celecoxib (CBX) (200 mg/24 h) or aceclofenac (ACF) (100 mg/12 h) for 3
months22. Ten patients who agreed to participate in the study but preferred
not to be treated with NSAID were also recruited to the study and used as
control (CTR) group22. Because of different technical problems ﬁve of the
30 patients enrolled into the study were excluded. So, the number of patients
that completed the study was as follows: nine for the CBX group, seven for
the ACF group and nine for the CTR group22. As previously described, OA
patients at the baseline visit had similar clinical characteristics, and the
Western Ontario and McMaster Universities Index of Osteoarthritis
(WOMAC) questionnaire rendered identical results for the three groups22.
During surgery, two different fragments from the medial femoral condyle of
each patient were excised and immediately frozen to carry out further
gene and protein expression studies. Two additional specimens from the
same region were dissected to perform histopathological studies.CARTILAGE HISTOPATHOLOGICAL STUDIESIn order to carry out histopathological studies on cartilage, two fragments
from the medial femoral condyle of each patient were dissected. After
macroscopic evaluation, the fragments were ﬁxed for 24 h in 4% paraformal-
dehyde, decalciﬁed for 6 weeks in an ethylenediaminetetraacetic acid
(EDTA) solution (2 mM EDTA, 0.5 mM tartrate sodium potassium, pH 1)
and embedded in parafﬁn.
The cartilage sections (4 mm) were stained with hematoxylineeosin and
Alcian blue, and the histopathological alterations were evaluated using the
Mankin’s grading system23 in a blinded fashion. The histopathological study
for each patient was carried out in the most damaged zone of the cartilage. A
partial score for each category of the Mankin scale (structure abnormalities,
cellularity, matrix staining and tidemark integrity) was attributed, and these
scores were combined for each section.CELL CULTUREChondrocytes were obtained from the knee articular cartilage of different
OA patients included in the in vivo study (fulﬁlling American College of Rheu-
matology (ACR) criteria for functional class III or IV) and that underwent joint
replacement surgery at the Orthopaedic Surgery Department of the Funda-
cio´n Jime´nez Dı´az24. The global Mankin scores for the cartilage used to ob-
tain chondrocytes cultures ranged from 11.5 to 12.5. Informed consent was
obtained from each patient, as was the approval of the local ethical
committee.In each experiment, cells were deprived of serum for 48 h and then they
were stimulated with 10 u/ml IL-1b (Immunogenex, LA, CA, USA). Where in-
dicated, the cells were incubated with CBX (106 M, Pﬁzer, NY, USA) or diclo-
fenac (DCF, 106 M, Sigma, St. Louis, MO, USA) for 60 min prior to
stimulation, and the cells were maintained in the presence of these com-
pounds throughout the experiment period. In the in vitro studies DCF was
used instead of ACF because it is the main active metabolite of ACF25. NSAID
were tested at the concentration which correspond to the mean peak plasma
concentration after oral administration of a single therapeutic dose26,27.GENE EXPRESSION STUDIES USING REAL-TIME
POLYMERASE CHAIN (PCR)For gene expression studies, quiescent cells were incubated with 10 u/ml
IL-1b in the presence or absence of the drugs. Total RNA from the cartilage
or from the cultured chondrocytes was obtained using the RNeasy Lipid
Tissue Kit (Qiagen Inc, Valencia, CA, USA). The High-capacity cDNA Archive
kit (AppliedBiosystems, FosterCity, CA,USA)was used to generate cDNAs22.
RNA quantiﬁcation was performed by single-reporter real-time PCR using the
ABI Prism 7500-Sequence Detection system (Applied Biosystems)22. We
used speciﬁc TaqMan assays inventoried for COX-2, mPGES-1, iNOS, EP1,
EP2,EP3,EP4, IL-1b, and tumor necrosis factor alpha (TNFa) (all fromApplied
Biosystems). A pre-designed 18S rRNA assay (Applied Biosystems) was also
used as an endogenous control. mRNA expression was normalized to that of
18S rRNA in each well. Moreover, each patient or experimental point for each
gene was then normalized relative to the calibrator value (one of the CBX pa-
tients or unstimulated cells in each experiment were chosen as calibrator¼ 1).WESTERN BLOT ANALYSISFor protein studies, quiescent cells were incubated with 10 u/ml IL-1b in the
presence or absence of drugs for 24 h. Cartilage proteins from each patient or
from cultured chondrocytes were homogenized with ice-cold lysis buffer [1%
Nonidet P-40 (Sigma); 0.5% sodium dodecyl sulfate, 0.1 M EDTA, 1 M dithio-
threitol, and 1 M phenylmethylsulphonylﬂuoride in phosphate buffered saline].
The lysates were transferred to Eppendorf tubes and centrifuged twice at
12,000g for 10 min. Theprotein concentrationwasdeterminedby theBicincho-
ninic acid (BCA) method (Pierce, Rockford, IL, USA). Western blot studies
were performed as described previously24. The extracts were probed with
primary antibodies against human COX-2 (Santa Cruz Biotech, Heidelberg,
Germany), mPGES-1 (Cayman Chemicals Ann Arbor, MI, USA), iNOS
(Chemicon, CA, USA), TNFa (Peprotech, London, UK) and IL-1b (MBL,
Woburn, MA, USA). Each membrane was probed with anti-a-tubulin (Sigma)
to ensure equal protein loading, and the immunoreactivity of each protein was
then fully corrected for that of a-tubulin. The data are shown as the mean -
 s.e.m. of arbitrary densitometry units for each group.PGE2 ASSAYPGE2 was determined in cell supernatants as described previously28.NITRITE ASSAYThe quantity of nitrites in the culture medium was measured by the Griess
method. Quiescent cells were incubated for 24 h with 10 u/ml IL-1b in the
presence or absence of drugs, and equal volumes of supernatant and Griess
reagent (1% sulfanilamide, 0.1% N-1-naphthylethylenediamide dihydrochlor-
ide in 5% H3PO4) were incubated at room temperature for 10 min. The
absorbance was measured at 570 nm and the concentration of nitrites was
calculated using a standard curve.STATISTICAL ANALYSISAll statistical analyses were performed using SPSS 11.0 (SPSS Inc) and
the results were expressed as the mean S.E.M. Data from multiple groups
were compared by KruskaleWallis non-parametric analysis, and a pairwise
comparison using the ManneWhitney test was applied when overall differ-
ences were identiﬁed. Differences were considered signiﬁcant when the
P-value was less than 0.05.ResultsCARTILAGE HISTOPATHOLOGYAll cartilage specimens stainedwith hematoxylineeosin and
Alcianbluewereevaluated.Thepredominanthistopathological
Fig. 1. COX-2 gene expression and protein accumulation in the ar-
ticular cartilage of patients treated with CBX or ACF and CTR pa-
tients, as well as in cultured cells pre-incubated for 60 min with
CBX (106 M) and DCF (106 M), and then stimulated with 10 u/
ml IL-1b for 24 h. (A) COX-2 expression measured by real-time
PCR using the comparative Ct method for relative quantiﬁcation.
COX-2 mRNA expression was normalized to the 18S rRNA in
each well, and the gene expression for each patient was then
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pocellular cartilage with frequent cellular clones, mild to
moderate reduction of the matrix staining score and crossing
of the tidemark by blood vessels. These changes were scored
for each sample as described in the Patients and methods
section. The global Mankin scores for each group were
10.9 0.6 for CBX; 12.2 0.7 for ACF; and 11.2 0.6 for
CTRpatients.Nosigniﬁcant differenceswereseen in thisscore
between the three patient groups studied either in the global
Mankin score or in any of the four subscales evaluated.COX-2 EXPRESSION AND SYNTHESISIn vivo: The expression of COX-2 mRNA in the cartilage
from OA patients was assessed by real-time PCR studies.
Both CBX and ACF produced a signiﬁcant decrease in
COX-2 gene expression when compared to CTR group
[Fig. 1(A)]. Moreover, no signiﬁcant difference was
observed between patients treated with CBX and ACF
[Fig. 1(A)]. The presence of COX-2 protein was diminished
in CBX treated patients when compared to the CTR group
[Fig. 1(B)] and although ACF displayed a similar trend, the
difference was not statistically signiﬁcant. Again, there
was no signiﬁcant difference in COX-2 accumulation
between CBX and ACF patients [Fig. 1(B)].
In vitro: IL-1b induced a 29-fold increase in the production
of COX-2 [Fig. 1(C)] and both CBX and DCF inhibited COX-
2 synthesis induced by IL-1b. Exposure to NSAID alone did
not modify COX-2 synthesis observed under basal condi-
tions [Fig. 1(C)].mPGES-1 EXPRESSION AND SYNTHESISIn vivo: Both CBX and ACF signiﬁcantly inhibited
mPGES-1 gene expression in the cartilage of the OA
patients when compared to CTR patients [Fig. 2(A)]. There
was no signiﬁcant difference in expression between CBX
and ACF treated patients. CBX treatment also decreased
mPGES-1 protein accumulation in the cartilage when
compared with the CTR group [Fig. 2(B)] and although
ACF treatment produced a similar trend, the difference
was not statistically signiﬁcant [Fig. 2(B)].
In vitro: In cultured chondrocytes, IL-1b induced a signiﬁ-
cant increase in mPGES-1 protein synthesis [Fig. 2(C)] that
was inhibited by both NSAID. In unstimulated chondrocytes
NSAID did not modify mPGES-1 synthesis observed under
basal conditions [Fig. 2(C)].EP RECEPTOR EXPRESSIONIn vivo: PCR studies revealed that OA cartilage expressed
all the EP receptors. No difference was observed in the
expression of EP1 or EP3 between the groups included in
this study [Fig. 3(A andC)]. However, CBX treatment induced
a signiﬁcant decrease in the expression of EP2 receptor
when compared both to ACF and CTR groups and of EP4
receptor compared with CTR patients [Fig. 3(B and D)].normalized relative to the calibrator value (one of the CBX patients
was chosen as calibrator¼ 1). A representative Western blot of
COX-2 and a-tubulin and the densitometric analysis of COX-2
levels expressed in densitometric arbitrary units (DAU) after correc-
tion by a-tubulin for patients (B) and cultured cells (C) are shown.
Data represent mean  S.E.M. #P < 0.05 vs CTR patients;
*P< 0.05 vs basal; yP< 0.05 vs IL-1b.
Fig. 2. mPGES-1 gene expression and protein accumulation in the ar-
ticular cartilage of patients treated with CBX or ACF and CTR patients,
as well as in cultured cells pre-incubated for 60 min with CBX (106 M)
and DCF (106 M), and then stimulated with 10 u/ml IL-1b for 24 h. (A)
mPGES-1 expression measured by real-time PCR using the compara-
tive Ct method for relative quantiﬁcation. mPGES-1 mRNA expression
was normalized to the 18S rRNA in each well, and the gene expression
in each patient was then normalized relative to the calibrator value (one
of the CBX patients was chosen as calibrator¼ 1). A representative
Western blot of mPGES-1 and a-tubulin and the densitometric analysis
ofmPGES-1 levelsexpressed inDAUafter correction fora-tubulin inpa-
tients (B)andculturedcells (C)areshown.Data representmean S.E.M.
#P< 0.05 vs CTR patients; *P< 0.05 vs basal; yP< 0.05 vs IL-1b.
1487Osteoarthritis and Cartilage Vol. 16, No. 12In vitro: In cultured chondrocytes, IL-1b did not modify
EP1 and EP3 gene expression at any of the times studied,
while a signiﬁcant increase in the EP2 and EP4 gene
expression was observed after 4 h of stimulation with the
cytokine (data not shown). However, neither CBX nor
DCF modiﬁed the up-regulation of EP2 and EP4 gene
expression induced by exposure of chondrocytes to IL-1b
for 4 h. Exposure to NSAID alone did not modify the EP
gene expression observed under basal conditions
[Fig. 4(A and B)].iNOS EXPRESSION AND SYNTHESISIn vivo: The expression of iNOS was diminished in
patients treated with CBX and ACF when compared to the
CTR group [Fig. 5(A)], although the difference in iNOS
expression between CBX and ACF patients was not signif-
icant [Fig. 5(A)]. Both ACF and CBX treated patients
displayed a signiﬁcant decrease in the accumulation of
iNOS protein when compared to CTR patients [Fig. 5(B)]
and again there was no signiﬁcant difference between the
two treatments.
In vitro: In cultured chondrocytes, IL-1b induced a signiﬁ-
cant increase in the synthesis of iNOS protein [Fig. 5(C)]
and this increase was not modiﬁed by exposure to CBX
or DCF. In unstimulated chondrocytes NSAID did not
modify iNOS synthesis observed under basal conditions
[Fig. 5(C)].PGE2 AND NO CONCENTRATIONS IN CELL SUPERNATANTSIn vitro: The release of PGE2 and NO was measured
after stimulation for 24 h with IL-1b in cell-conditioned
medium. IL-1b caused a signiﬁcant rise in PGE2 release
[Fig. 6(A)] whereas both NSAID evoked a signiﬁcant
decrease in basal PGE2 production when compared to
unstimulated cells [Fig. 6(A)]. CBX signiﬁcantly diminished
PGE2 levels in IL-1b treated chondrocytes when compared
to the IL-1b stimulated cells [Fig. 6(A)]. DCF caused a dra-
matic decrease in PGE2 levels in IL-1b treated chondro-
cytes, not only when compared to IL-1b stimulated cells
but also with respect to the CBX incubated cells [Fig. 6(A)].
IL-1b stimulation for 24 h increased the NO concentration
in cell supernatants by 25-fold. However, neither CBX nor
DCF altered the increase induced by IL-1b. In unstimulated
cells NSAID did not modify NO concentration observed
under basal conditions [Fig. 6(B)].IL-1b AND TNFa EXPRESSION AND SYNTHESISIn vivo: Interestingly, the expression of the IL-1b and
TNFa genes was signiﬁcantly diminished by CBX treatment
in the cartilage of OA patients when compared to the CTR
patients and when compared to ACF treated patients
[Fig. 7(A and D)]. However, ACF did not modify the expres-
sion of these cytokines in the cartilage [Fig. 7(A and D)]. In
terms of protein production, neither CBX nor ACF modiﬁed
the production of IL-1b in comparison with the CTR group
[Fig. 7(B)]. By contrast, CBX treatment induced a signiﬁcant
decrease in the TNFa accumulation when compared to the
CTR group. No signiﬁcant difference was found between
ACF and CTR patients [Fig. 7(E)].
In vitro: In cultured chondrocytes, IL-1b stimulation
elicited a signiﬁcant increase in IL-1b and TNFa gene
expression after 2 h of incubation [Fig. 7(C and F)]. Both
CBX and DCF prevented this increase, and no signiﬁcant
difference was found between them [Fig. 7(C)]. With
Fig. 3. EP receptors’ gene expression in the articular cartilage of patients treated with CBX or ACF, and CTR patients. EP1 (A), EP2 (B), EP3
(C) and EP4 (D) expressions measured by real-time PCR using the comparative Ct method for relative quantiﬁcation. EP receptors’ mRNA
expression was normalized relative to the 18S rRNA in each well, and the gene expression in each patient was then normalized relative to the
calibrator value (one of the CBX patients was chosen as calibrator¼ 1). Data represent mean S.E.M. #P< 0.05 vs CTR patients; &P< 0.05
vs ACF patients.
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cytokine expression in the stimulated chondrocytes
[Fig. 7(F)]. In unstimulated chondrocytes NSAID modiﬁed
neither IL-1b nor TNFa gene expression observed under
basal conditions [Fig. 7(C and F)].Discussion
While traditional NSAID and selective COX-2 inhibitors
are commonly employed to treat rheumatic diseases such
as OA, and they are often administered over long periods,
their direct effects on chondrocytes and articular cartilage
remain poorly understood. The effects of NSAID are derived
mainly from their ability to inhibit COX activity, thereby
decreasing PGE2 synthesis. Besides mediating pain and
inﬂammation in OA, PGE2 plays a role in the degeneration
of the cartilage associated with the disease29.
In the present study, we have demonstrated that NSAID
treatment inhibited both COX-2 and mPGES-1 expression
and synthesis in the cartilage of OA patients, the key
enzymes in the synthesis of PGE2. We have also demon-
strated that in IL-1b stimulated chondrocytes in culture,
both NSAID inhibited COX-2 and mPGES-1 expression
and synthesis. These results are in agreement with previ-
ously published data regarding the inhibition of COX-2 ex-
pression in leukemic and lung carcinoma cells and in
synoviocytes in the presence of different NSAID30,31.Indeed, a selective COX-2 inhibitor reduced COX-2 in
cartilage explants in an experimental model of OA32.
According to our data, both NSAID exerted a similar
inhibition of COX-2 and mPGES-1 production in human
OA cartilage. These enzymes are induced strongly in OA
cartilage and they are responsible for the increase in
PGE2 concentration13,29. We have previously demon-
strated that both CBX and ACF inhibited PGE2 production
to a similar extent in knee synovial ﬂuid from OA patients22,
and they also inhibited COX-2 expression and synthesis in
the OA synovial membrane. The PGE2 concentration in the
synovial ﬂuid diminished by about 60%, due to the action of
NSAID on PGE2 release in the synovial and, in a much
lesser extent, in the cartilage. Indeed, most NSAID appear
to dramatically inhibit cellular PGE2 release in vitro28,33e35.
Nevertheless, differences in the studies of the action of
PGE2 on cartilage may be at least partially due to this
distinct in vivo and in vitro inhibition of PGE2 evoked by
different NSAID.
The mechanism by which COX-2 and mPGES-1 might be
inhibited in the cartilage in the presence of diminished
PGE2 concentration remains unknown. Taking account
our in vitro results, the chondrocytes might be responsible
for these effects because they are the only cell type in the
cartilage. Recent data demonstrated that PGE2 is able to
regulate its own synthesis stabilizing COX-2 mRNA in
synoviocytes36. In the same way, PGE2 is also an enhancer
of mPGES-1 expression37.
Fig. 4. EP2 and EP4 gene expression in cultured cells pre-incu-
bated for 60 min with CBX (106 M) and DCF (106 M), and then
stimulated with 10 u/ml IL-1b for 4 h. EP2 (A) and EP4 (B) mRNA
expression was normalized relative to the 18S rRNA in each well,
and the gene for each experimental point was then normalized
relative to the calibrator value (unstimulated cells were chosen as
calibrator¼ 1). Data represent mean S.E.M. *P< 0.05 vs basal.
1489Osteoarthritis and Cartilage Vol. 16, No. 12In Spain ACF is frequently preferred to other NSAID in
the treatment of advanced knee OA in patients in which
paracetamol and ibuprofen become uneffective because
of its safety proﬁle38. Some preferential COX-1 inhibitors
are not allowed for their general use in knee OA. So, ACF
was chosen in the clinical trial as comparator to a COXIB.
In humans, ACF is rapidly metabolized to 40-hydroxyaceclo-
fenac, DCF and 40-hydroxydiclofenac39. With regards to
PGE2 synthesis, it has been demonstrated that ACF and
40-hydroxyaceclofenac have no inhibitory effect on COX
activity. Indeed, they are only able to suppress PGE2
production following their conversion into DCF and
40-hydroxydiclofenac25,40.
Four different prostaglandin (PG) receptors (EP recep-
tors) have been identiﬁed to date20, and although their
expression in human OA cartilage has been little studied,
they are thought to be present in rat growth plate chon-
drocytes41,42. Our data revealed that cultured chondro-
cytes are able to express all the EP receptors, although
IL-1b stimulation only increased EP2 and EP4 gene ex-
pression. In our experimental conditions, neither CBX nor
DCF was able to signiﬁcantly modify the EP2 or EP4
receptor expression induced by IL-1b. In the in vivostudies, we have shown that both EP1 and EP3 receptors
are present in the OA cartilage but we did not ﬁnd any
inﬂuence of NSAID treatment on their gene expression.
However, CBX provoked a signiﬁcant decrease in both
EP2 and EP4 expression in OA patients. EP2/EP4 medi-
ated PGE2 signaling has been implicated in joint inﬂamma-
tion and in the cartilage and bone extracellular matrix
degradation in different experimental models of arthritis43,44.
The reduction in the EP2/EP4 expression observed in the
cartilage of the CBX treated patients would help to control
the inﬂammatory response and the progression of the
cartilage damage. Hence, it is important to note that EP2/
EP4 mediated PGE2 signaling may also have an anti-in-
ﬂammatory role at least in situations of complete PGE2
depletion28.
Our results showed that both CBX and ACF decreased
iNOS gene expression and synthesis in human OA carti-
lage. However, none of the NSAID used in the in vitro
experiments were able to signiﬁcantly decrease neither
NO concentration nor iNOS expression in human chondro-
cytes. Nevertheless, our in vivo results are in agreement
with previous data regarding the down-regulation in iNOS
expression by NS-398 in OA cartilage explants32. The ap-
parent contradiction between the in vivo and in vitro results
has also been observed by other investigators, suggesting
that COX-2 inhibitors decrease NO production in instability
or compression-induced OA models, but not in IL-1 in-
duced models45. However, we cannot rule out that the re-
duction in iNOS gene expression and synthesis in vivo
could be due to the decrease in the overall inﬂammatory
state that occurs after long-term treatment with CBX or
ACF.
Therefore, our data suggest that NSAID therapy would
inhibit local PGE2 concentration by directly inhibiting the
expression and synthesis of the inducible enzymes respon-
sible for PGE2 synthesis in the cartilage. Furthermore, EP2/
EP4 down-regulation would help to reduce the progression
of joint damage. CBX and ACF treatment would also
decrease the release of NO in the cartilage by inhibiting
iNOS production in this tissue. To our knowledge, this study
constitutes the ﬁrst report of the regulation of COX-2,
mPGES-1, EP receptors and iNOS synthesis by NSAID in
human OA cartilage.
Increased IL-1b and TNFa levels are detected in joint
tissues and synovial ﬂuid of OA patients46,47 and were cor-
related with cartilage damage46,48. We have shown that
CBX inhibited TNFa gene expression and protein accumu-
lation in the cartilage of OA patients. CBX also inhibited IL-
1b gene expression, although we did not observe any effect
on the amount of IL-1b protein, probably due to the broad
distribution of the data. In vitro, both CBX and DCF signiﬁ-
cantly diminished the increase in IL-1b expression in stimu-
lated cells, while the NSAID did not modify TNFa
expression. These results did not reﬂect the situation in
vivo, but due to the complexity of the inﬂammatory and met-
abolic signaling pathways that lead to joint destruction, it is
conceivable that the in vitro and in vivo effects of the NSAID
could differ.
As hypothesized, prostaglandins are not the sole target
of the anti-inﬂammatory action of NSAID49. Our data
demonstrate that the chondrocyte response to different
NSAID with regards to IL-1b and TNFa differs in vivo and
it does not depend on the local concentration of PGE2.
This is similar to the described effect of NSAID on the
control of IL-6 synthesis in chondrocytes35. We have previ-
ously demonstrated that both CBX and ACF exert a similar
PGE2 and COX-2 inhibitory proﬁle, while their effects on
Fig. 5. iNOS gene expression and protein accumulation in the artic-
ular cartilage of patients treated with CBX or ACF and CTR pa-
tients, as well as in cultured cells pre-incubated for 60 min with
CBX (106 M) and DCF (106 M), and then stimulated with 10 u/
ml IL-1b for 24 h. (A) iNOS expression measured by real-time
PCR using the comparative Ct method for relative quantiﬁcation.
iNOS mRNA expression was normalized relative to the 18S rRNA
in each well, and the gene expression for each patient was then
normalized relative to the calibrator value (one of the CBX patients
was chosen as calibrator¼ 1). A representative Western blot of
iNOS and a-tubulin and the densitometric analysis of iNOS levels
expressed in DAU after correction for the a-tubulin in patients (B)
Fig. 6. Effect of CBX and DCF on the accumulation of PGE2 and
nitrite in cell supernatants. Cells were pre-incubated for 60 min
with CBX (106 M) and DCF (106 M), and then stimulated with
10 u/ml IL-1b for 24 h. Conditioned media were collected after
24 h to measure PGE2 and NO. (A) PGE2 and (B) NO in chondro-
cyte culture. Concentrations are shown as mean S.E.M. of three in-
dependent experiments. In each of them the PGE2 and NO were
measured in triplicate. *P < 0.05 vs basal; yP < 0.05 vs IL-1b;
zP< 0.05 vs CBXþ IL-1b.
1490 M. A. Alvarez-Soria et al.: Effect of long-term NSAID treatment on human OA cartilagesynovial cytokine synthesis are different22. Although further
studies are needed to clarify the effects of NSAID over
different pro-inﬂammatory and structural mediators, agents
that can inhibit cytokine expression in OA joints seem to be
particularly attractive targets for the development of OA
therapies.
During the OA process, chondrocytes and synovial ﬁbro-
blasts show independent capacities to initiate and respond
to injury, ultimately resulting in the degeneration of all the
structures of the joint. Pro-inﬂammatory factors produced
by chondrocytes and synovial cells are locally increased dur-
ing OA and induce a large cascade of events that lead to joint
damage. We have previously demonstrated that in patients
with knee OA, long-term NSAID treatment with both CBX
and ACF similarly improved joint pain and function and in-
hibited PGE2 concentration in synovial ﬂuid22. Our results in-
dicate that prolonged therapy with PGE2 blocking agents
decreases PGE2 production not only by direct inhibition ofand cultured cells (C) are shown. Data represent mean S.E.M.
#P< 0.05 vs CTR patients; *P< 0.05 vs basal.
Fig. 7. IL-1b and TNFa gene expression and protein accumulation in the articular cartilage of patients treated with CBX or ACF and CTR pa-
tients, as well as in cultured cells pre-incubated for 60 min with CBX (106 M) and DCF (106 M), and then stimulated with 10 u/ml IL-1b for
2 h. IL-1b gene expression measured using the comparative Ct real-time PCR method in OA patients (A) and in cultured cells (C). IL-1bmRNA
expression was normalized relative to the 18S rRNA in each well, and the gene for each patient value or experimental point was then nor-
malized relative to the calibrator value (one of the CBX patients or unstimulated cells were chosen as calibrator¼ 1). (B) A representative
Western blot of IL-1b and a-tubulin and the densitometric analysis of IL-1b levels expressed in DAU after correction for a-tubulin in the patients
are shown. TNFa expression measured by real-time PCR in OA patients (D) and in culture cells (F) also using the comparative Ct method for
relative quantiﬁcation. (E) A representative Western blot of TNFa and a-tubulin and a densitometric analysis of TNFa levels expressed in
DAUs after correction by a-tubulin for patients are shown. Data represent mean S.E.M. #P< 0.05 vs CTR patients; &P< 0.05 vs ACF
patients; *P< 0.05 vs basal; yP< 0.05 vs IL-1b.
1491Osteoarthritis and Cartilage Vol. 16, No. 12
1492 M. A. Alvarez-Soria et al.: Effect of long-term NSAID treatment on human OA cartilageCOX-2 activity, but also by down-regulating COX-2 and
mPGES-1 expression and synthesis in the articular cartilage
and in the synovial membrane of OA patients. The down-reg-
ulation of iNOS in the articular cartilage would also contribute
to reduce the progression of the inﬂammatory response.
However, CBX and ACF seem to have a different anti-inﬂam-
matory effect on cytokine synthesis both in the cartilage and
in the synovial membrane of OA patients.Conﬂict of interest
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